Intrapyloric injection of botulinum toxin a for the treatment of persistent gastroparesis following successful pancreas transplantation.
Intrapyloric injection of botulinum toxin A (BoTx) successfully improved symptoms in idiopathic and diabetic gastroparesis (DGP) refractory to medical treatment. Therefore, we used it in three pancreas transplant patients done in our institution during the last 18 months. They had severe, persistent DGP despite successful pancreas transplantation. They received 100 units of BoTx during the first injection. The clinical effect became evident within 2 weeks after the treatment, and lasted for an average of 29 weeks (range 14-44 weeks). The patients' subjective evaluation showed improvement of their symptoms and quality of life following BoTx. Patients 2 and 3 had recurrent symptoms at 44 and 24 weeks, respectively, after the first injection; they required a second dose of 90 and 80 units, respectively. They are doing well at 3 months follow-up. Intrapyloric injection of BoTx is safe and efficient. It should be considered for treating residual DGP following successful pancreas transplantation.
Ben-Youssef
R
R
Transplantation Institute, Loma Linda University Medical Center, Loma Linda, California, USA.
Baron
P W
PW
Franco
E
E
Walter
M H
MH
Lewis
T
T
Ojogho
O
O
D000328:Adult; D001905:Botulinum Toxins / Q000008:administration & dosage / Q000627:therapeutic use*; D003922:Diabetes Mellitus, Type 1 / Q000150:complications* / Q000601:surgery; D016099:Endoscopy, Gastrointestinal; D005260:Female; D018589:Gastroparesis / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007267:Injections; D016035:Pancreas Transplantation; D011708:Pylorus; D016896:Treatment Outcome
D001905:Botulinum Toxins